Preparation method and application of amphiphilic tyrosinase copper competitive binding agent

By synthesizing porphyrin compounds P4TA and P2TA, the problems of high toxicity and poor absorption of existing tyrosinase inhibitors are solved, and the efficient inhibition of tyrosinase and copper ion binding is achieved, and copper ion metabolism is provided. New ideas for intervention have potential in disease treatment.

CN118894864AActive Publication Date: 2024-11-05JIANGSU UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410951364.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-05
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Existing tyrosinase inhibitors are highly toxic, natural polyphenol compounds have weak inhibition of tyrosinase and poor cell absorption, and lack tyrosinase targeting agents for copper ion metabolism intervention.

Method used

Synthesize new phenol-based coupled porphyrin compounds and metal complexes P4TA and P2TA. By optimizing the synthesis process, they explore their binding effects with copper ions and tyrosinases, and found that they have significant inhibitory effects and amphiphilic properties. .

Benefits of technology

P4TA and P2TA significantly improve the inhibition rate of tyrosinase, have good copper ion binding ability and tyrosinase targeting, and have the first reported multi-effect tyrosinase inhibitors, with copper ions in disease treatment. The potential of metabolic intervention.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894864A_ABST
    Figure CN118894864A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of an amphiphilic tyrosinase copper competitive binding agent. According to the invention, tyramine TA and 4, 4 ', 4' ', 4 '''-(porphyrin-5, 10, 15, 20-tetrayl) tetrabenzoic acid TCPP or 3, 7, 12, 17-tetramethyl-8, 13-diethyl-2, 18-porphyrin dipropionic acid PPIX are coupled to synthesize two new compounds P4TA or P2TA, and the two new compounds P4TA or P2TA are synthesized into the compound. The invention also provides an optimal synthesis process of P4TA and P2TA, and provides experience for related synthesis. The obtained P4TA and P2TA can recognize tyrosinase and are good copper ion binding reagents, and the two compounds show a remarkable inhibition effect on TYR. The compound can be used for tyrosinase targeted inhibition and copper ion metabolism intervention in biological medicine and food.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an amphipathic tyrosinase copper competitive binder, and belongs to the field of tyrosinase recognition and inhibitors, and particularly refers to an amphipathic multi-effect tyrosinase copper competitive binder and its application in tyrosinase inhibition, which can be used for tyrosinase targeted inhibition and copper ion metabolism intervention in biomedicine and food. Background Art

[0002] The potential applications of compounds recognized by tyrosinase (TYR) in the treatment of cancer, neurodegenerative diseases, metabolic diseases and bacterial resistance have become a research hotspot. In recent years, studies have found that tyrosinase is involved in the degradation and metabolism of tyrosine. The design and development of tyrosinase inhibitors can block the metabolic pathways of bacteria, thereby inhibiting their growth and reproduction [ECJ Syed, LL Grima, PJ Magill, R. Bogacz, P, Brown, ME Walton, Action initialization shapes mesolimbic dopamine encoding of future rewards. Nat. Neurosci. 19 (2016) 34-36; S. Zolghadri, A. Bahrami, MT Hassan-Khan, J. Munoz-Munoz, F. Garcia-Molina, F. Garcia-Canovas, AA Saboury, A comprehensive review on tyrosinase inhibitors, J. Enzyme Inhib. Med. Chem. 34 (2019) 279–309.], therefore, tyrosinase inhibitors have become a hot topic in the field of drug research and development.

[0003] As a polyphenol oxidase, TYR first catalyzes monophenols to produce bisphenols, and then further oxidizes them into o-quinones; for example, under the catalytic action of TYR, tyramine (TA) is successively converted into dopamine, dopamine o-quinone and other substances. This process has been applied to the development of responsive probes. In 2020, researchers developed a fluorescent probe with phenol as an enzyme substrate [S. Yang, JX Jiang, AX Zhou, YB Zhou, WLY e, DSCao, RHYang, Substrate-photocaged enzymatic fluorogenic probe enabling sequential activation for light-controllable monitoring of intracellular tyrosinase activity. Anal. Chem. 92 (2020) 7194-7199.]. The fluorescence of this probe can be "turned on" by ultraviolet light and TYR. The results of fluorescence imaging confirmed that the probe can visualize the endogenous activity of cell TYR under light-controlled conditions.

[0004] Based on the recognition characteristics of TYR for TA, we selected TA as the recognition part, and improved the amphiphilicity of porphyrin compounds by adjusting the coupling structure of TA and porphyrin, thereby increasing the multi-effect action points of such compounds and TYR. Although tyrosine inhibitors have been reported [TNPham, EACazier, E.Gormally, P.Lawrence, Valorization of biomasspolyphenols as potential tyrosinase inhibitors, Drug Discovery Today, 29 (2023) 103843], most synthetic heterocyclic tyrosinase inhibitors are highly toxic, and natural polyphenol compounds have weak inhibition on tyrosinase and poor cell absorption [XWZhang, GLBian, PYKang, XYCheng, K.Yan, YLLiu, YXGao, DQLi, Recent advance in the discovery of tyrosinase inhibitors from natural sources via separation methods, J.Enzyme Inhibition Med.Chem.36(2021)2104-2117], there are no reports on amphiphilic compounds based on competitive binding of copper in the active center of tyrosinase. In order to develop tyrosinase-targeted copper binders, the present invention synthesizes new phenol-coupled porphyrin compounds and metal complexes. The research results will provide new ideas and methods for discovering more effective tyrosinase inhibitors and antibacterial agents for copper ion metabolism. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention couples tyramine (labeled as TA) with 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrabenzoic acid (labeled as TCPP) or 3,7,12,17-tetramethyl-8,13-diethyl-2,18-porphyrin dipropionic acid (labeled as PPIX) to synthesize two new compounds, 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrakis(p-hydroxyphenylethyl)formamide (labeled as P4TA) and 3,3'-(3,7,13,17-tetramethyl-8,12-divinylporphyrin-2,18-diyl)bis(N-(4-hydroxyphenylethyl)propionamide) (labeled as P2TA). The optimal synthesis process of P4TA and P2TA is explored, providing an experience for related synthesis. Next, the binding of P4TA and P2TA to copper ions and tyrosinase (TYR) was studied. It was found that P4TA and P2TA can recognize tyrosinase and are good copper ion binding agents. The two compounds showed significant inhibitory effects on TYR. In addition, P4TA is soluble in dichloromethane and methanol, slightly soluble in water, and is an amphiphilic copper ion binding agent and a good tyrosinase inhibitor. The structures of P2TA and P4TA are as follows:

[0006]

[0007]

[0008] The preparation method of P4TA or P2TA comprises the following steps:

[0009] 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrabenzoic acid (labeled as TCPP) or 3,7,12,17-tetramethyl-8,13-diethyl-2,18-porphyrin dipropionic acid (labeled as PPIX) is mixed with pyridine in proportion, and then 1-hydroxybenzotriazole HOBt, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDCI and N,N-diisopropylethylamine DIPEA are added dropwise; then the mixed solution is stirred at room temperature in the dark for 1 to 3 hours, and then tyramine TA is added and stirred for 3 to 12 hours; petroleum ether is added to the above system, and a precipitate is obtained by filtration, and then extracted with DCM and water, dried with anhydrous sodium sulfate, and then subjected to rotary distillation or silica gel column chromatography to obtain P4TA purple-red solid or P2TA purple-red solid.

[0010] Furthermore, when the raw material is TCPP,

[0011] The mass ratio of TCPP to pyridine is 1:10 to 1:60, preferably 1:40.

[0012] The molar ratio of TCPP:HOBt:EDCI:DIPEA is 1:1:1:1 to 1:8:8:8, preferably 1:3:3:3;

[0013] The molar ratio of TCPP: tyramine TA is 1:2 to 1:16, preferably 1:12;

[0014] Furthermore, when the raw material is PPIX,

[0015] The mass ratio of PPIX to pyridine is 1:10 to 1:60, preferably 1:40.

[0016] The molar ratio of PPIX:HOBt:EDCI:DIPEA is 1:1:1:1 to 1:4:4:4, preferably 1:2:2:2;

[0017] The molar ratio of PPIX: tyramine TA is 1:2 to 1:8, preferably 1:6;

[0018] In the above steps,

[0019] The mixed solution is stirred at room temperature away from light for 1 to 3 hours, preferably 1 hour;

[0020] After adding tyramine, the stirring time is 3 to 12 hours, and the best time is 8 hours;

[0021] The volume ratio of petroleum ether to pyridine is 10:1 to 60:1 (optimal 25:1).

[0022] During extraction, the volume ratio of DCM and water was 1:1.

[0023] The P4TA or P2TA prepared by the present invention is used for binding to tyrosinase, wherein P4TA is a better tyrosinase binding agent; the inhibition rate of 27 μM P4TA on tyrosinase reaches 88.63%, indicating that P4TA is a targeted tyrosinase inhibitor; in addition, P4TA and P2TA have a copper ion binding effect and can be used as copper competitive binding agents in tyrosinase. Therefore, P4TA and P2TA have multiple effects of tyrosinase recognition, copper ion binding and tyrosinase activity inhibition, and their good fat solubility and water solubility make them amphiphilic. Based on this, our P4TA is a multi-effect tyrosinase inhibitor. In the literature, tyrosinase inhibitors are used to interfere with the catalytic activity of tyrosinase. Here, we report for the first time a multi-effect tyrosinase inhibitor with tyrosinase recognition and copper ion binding, which is the first report in the world.

[0024] The beneficial effects of the present invention are:

[0025] (1) The present invention discloses the synthesis and purification process of P4TA or P2TA, and finds that when the alkaline solvent pyridine is used, the yield of the target product P4TA is significantly increased to 68.54%. Pyridine is selected as the best solvent for this reaction.

[0026] The relationship between the TA / TCPP ratio and the yield was further discovered. The results showed that when the TA / TCPP ratio was in the range of 4 to 12, the yield increased with the increase of the ratio, and reached its maximum value when the ratio reached 12.

[0027] (2) It was found that P4TA and P2TA have tyrosinase-targeted binding properties, with binding constants of 1127 and 30.9 for tyrosine (Tyr) residues in tyrosinase, and binding constants of 51.20 and 14.60 for tryptophan in tyrosinase, indicating that P4TA is a better tyrosinase binding agent.

[0028] (3) P4TA and P2TA are inhibitors of tyrosinase-catalyzed L-tyrosine oxidation. The IC50 concentration of P4TA for tyrosinase inhibition is 50 The inhibition rate of 9μM P4TA on tyrosinase is 50.61, and the IC 50 The inhibition rate of P4TA to tyrosinase is 13μM (the inhibition rate of 13μM P2TA to tyrosinase is 49.43%), and the inhibition rate of 27μM P4TA to tyrosinase reaches 88.63%, which shows that P4TA is a better tyrosinase inhibitor.

[0029] (4) P4TA and P2TA can bind Cu 2+ , the binding of copper ions is sensed by fluorescence changes. 2+ The results of fluorescence titration of the binding showed that Cu 2+ The fluorescence emission of P4TA and P2TA was significantly quenched, indicating that P4TA and P2TA have copper ion binding-sensitive probes.

[0030] In summary, P4TA and P2TA have multiple effects of tyrosinase recognition, copper ion binding and tyrosinase activity inhibition. Their good lipid solubility and water solubility make them amphiphilic. Based on this, we further proposed that the competitive binding between P4TA and tyrosinase and the copper ion in the enzyme active center achieves a synergistic enhancement mechanism for TYR inhibitory activity. The phenolic compounds in the literature have a weak inhibitory effect on tyrosinase, and this is the first report of a tyrosinase inhibitor with copper ion binding effect in the world. Copper ions and tyrosinase are related to diseases such as Alzheimer's disease, tumors, and bacterial resistance. Therefore, P4TA, as a tyrosinase-targeted copper ion and tyrosinase activity intervention reagent, is expected to be used in disease treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is the H NMR spectrum of P4TA in deuterated DMF.

[0032] Figure 2 This is the fluorescence emission spectrum of P4TA (5μM) under different copper ion effects. Curve ad is the copper ion concentration of 0, 1.50μM, 3.0μM, and 5.0μM.

[0033] Figure 3 This is the H NMR spectrum of P2TA in deuterated DMSO.

[0034] Figure 4 This is the fluorescence emission spectrum of P2TA (5μM) under different copper ion effects. Curve ad is the copper ion concentration of 0, 1.50μM, 3.0μM, and 5.0μM.

[0035] Figure 5 Excitation (ex) and emission (em) spectra of P2TA (5 μM) methanol solution.

[0036] Figure 6 This is the effect of P4TA on the synchronous fluorescence emission of tyrosine (tyr) in tyrosinase (86.7U / mL). Curves ah represent P4TA of 0μM, 3.33μM, 6.66μM, 9.99μM, 13.32μM, 16.65μM, 19.9μM8, and 26.64μM), respectively, and Δλ=15nm.

[0037] Figure 7 This is the effect of P4TA on the synchronous fluorescence emission of tryptophan (try) in tyrosinase (86.7U / mL). Curves ah represent P4TA of 0μM, 3.33μM, 6.66μM, 9.99μM, 13.32μM, 16.65μM, 19.9μM, and 26.64μM, respectively, and Δλ=60nm.

[0038] Figure 8 The inhibitory activity of different concentrations of P4TA on the oxidation reaction of tyrosine (1 mM) catalyzed by tyrosinase (800 μL, 260 U / mL). DETAILED DESCRIPTION

[0039] Reagents:

[0040] 3,7,12,17-Tetramethyl-8,13-diethyl-2,18-porphyrin dipropionic acid (common name: protoporphyrin, labeled as PPIX), 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrabenzoic acid (common name: porphyrin tetracarboxylic acid, labeled as TCPP), tyramine (TA), 1-hydroxybenzotriazole (HOBT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), and N,N-diisopropylethylamine (DIPEA) were purchased from Shanghai Anaiji Chemical Reagent Co., Ltd., and tyrosinase (TYR) (1120u / mg DW) was purchased from Yuanye Biotechnology Co., Ltd.

[0041] Example 1

[0042] The best synthesis scheme of 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrakis(p-hydroxyphenylethyl)benzamide (labeled as P4TA):

[0043] TCPP (50 mg, 0.06 mmol) was dissolved in 2 mL of pyridine, and 24 mg of HOBt (0.18 mmol), 35 mg of EDCI (0.18 mmol), and 0.12 g of DIPEA (0.18 mmol) were added respectively. The mixture was stirred at room temperature for 1 h in the dark, and then 137 mg of tyramine (0.72 mmol) was added. After stirring for 8 h, 50 mL of petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain a precipitate, which was then extracted with 50 mL of DCM and 50 mL of water; after drying with anhydrous sodium sulfate, 54 mg of purple-red solid was obtained by rotary distillation, and the yield was 71.3%. The NMR of the compound is attached. Figure 1 .

[0044] 1 H NMR(400MHz,DMF-d7)δ9.45(s,5H),8.98(d,J=22.9Hz,12H),8.50–8.22(m,16H ),7.21(d,J=8.3Hz,8H),6.91–6.74(m,8H),3.73(t,J=8.0Hz,8H),2.74(s,8H). 13 CNMR(101MHz,DMF-d7)δ167.54,166.54,156.62,144.59,134.83,131.74,130.35,129.97,129.07,126 .13,120.04,115.53,79.38,67.79,42.19,38.91,27.12,23.83,22.98,22.67,13.81,10.77.HR-MS(ESI + , MeOH):Calcd for [M+H]+ [C 50 H 53 N6O4] + :1266.5, found:1267.51.

[0045] Mass spectrometry data showed that the main particles of P4TA in methanol solution were [P4TA+H + ] + ,m / z=1267.51(100), which is the molecular ion peak of P4TA combined with a proton; the characteristic absorption peak of the porphyrin ring S band appears at 410nm in the DMSO solution of P4TA, and four groups of porphyrin Q band absorption peaks appear at 500~600nm, indicating the formation of the porphyrin ring. When excited at 420nm, P4TA shows strong fluorescence emission at 650nm and a broad fluorescence emission peak at 720nm ( Figure 2 Curve a) in .

[0046] Example 2 (Synthesis of P4TA)

[0047] TCPP (50 mg, 0.06 mmol) was dissolved in 3 mL of pyridine, and 32 mg of HOBt (0.24 mmol), 46 mg of EDCI (0.24 mmol), and 0.16 g of DIPEA (0.24 mmol) were added respectively. The mixture was stirred at room temperature for 3 h in the dark, and then 182 mg of tyramine (0.96 mmol) was added. After stirring for 12 h, 60 mL of petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain the precipitate, and then extracted with 50 mL of DCM and 50 mL of water respectively; after drying with anhydrous sodium sulfate, 12.1 mg was obtained by rotary distillation, with a yield of 16.0%

[0048] Example 3 (Synthesis of P4TA)

[0049] TCPP (50 mg, 0.06 mmol) was dissolved in 0.5 mL of pyridine, and 21 mg of HOBt (0.06 mmol), 30 mg of EDCI (0.06 mmol), and 0.11 g of DIPEA (0.06 mmol) were added respectively. The mixture was stirred at room temperature for 2 h in the dark, and then 23 mg of tyramine (0.12 mmol) was added. After stirring for 3 h, 30 mL of petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain a precipitate, which was then extracted with 50 mL of DCM and 50 mL of water; after drying with anhydrous sodium sulfate, 10 mg of purple-red solid was obtained by rotary distillation, and the yield was 13.2%.

[0050] Example 4 (Synthesis of P4TA)

[0051] TCPP (50 mg, 0.06 mmol) was dissolved in 2 mL of pyridine, and 64 mg of HOBt (0.48 mmol), 92 mg of EDCI (0.48 mmol), and 0.32 g of DIPEA (0.48 mmol) were added respectively. The mixture was stirred at room temperature for 1 h in the dark, and then 137 mg of tyramine (0.72 mmol) was added. After stirring for 8 h, 20 mL of petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain a precipitate, which was then extracted with 50 mL of DCM and 50 mL of water; after drying with anhydrous sodium sulfate, 39 mg of purple-red solid was obtained by rotary distillation, and the yield was 51.7%.

[0052] Example 5

[0053] The best synthesis example of 3,3'-(3,7,13,17-tetramethyl-8,12-divinylporphyrin-2,18-diyl)bis(N-(4-hydroxyphenylethyl)propionamide) (labeled as P2TA):

[0054] PPIX (34 mg, 0.06 mmol) was ultrasonically dissolved in 1.4 mL of pyridine; 16 mg of HOBt (0.12 mmol), 23.7 mg of EDCI (0.12 mmol), and 0.08 mg of DIPEA (0.12 mmol) were added, the mixture was stirred at room temperature for 1 h in the dark, and then 91.3 mg of tyramine (0.48 mmol) was added. After stirring at room temperature for 8 h under nitrogen protection, 35 mL of petroleum ether was added to the system, and the precipitate was filtered after stirring for 5 min, and then extracted with 50 mL of DCM and 50 mL of water; 50 mL of deionized water was added to wash the precipitate three times, and after drying with anhydrous sodium sulfate, the precipitate was separated by silica gel column chromatography, and the product was eluted with dichloromethane: ethyl acetate = 4: 1 (v: v), and 31.5 mg of purple-red solid was obtained, with a yield of 65%. The H NMR spectrum of P2TA is attached. Figure 3 .

[0055] 1H NMR (400MHz, DMSO-d6) δ10.31–9.96 (m, 3H), 9.08 (s, 2H), 8.43 (dt, J = 17.8, 11.1Hz, 2H), 8.09 (t, J = 5. 6Hz,2H),6.63(d,J=8.1Hz,4H),6.50–6.41(m,4H),6.40(dd,J=4.7,1.6Hz,1H),6.22(ddd,J=11.6,5.1 ,1.5Hz,2H),4.30(t,J=7.7Hz,4H),4.07(d,J=7.1Hz,1H),3.66(d,J=6.7Hz,5H),3.58(d,J=2.2Hz,5H ),3.14(q,J=6.9Hz,3H),3.03(t,J=7.5Hz,3H),2.23(t,J=7.6Hz,4H),2.03(s,1H),1.40–1.07(m,6H). 13 C NMR(101MHz,DMF-d7)δ172.27,155.99,140.30,130.45,129.62,129.46,129.35,120.55,114.95,114.87,97 .77,97.68,97.45,97.18,41.03,39.11,26.96,22.79,22.50,13.68,12.27,12.25,10.88,10.85.LR-MS(ESI + , MeOH):Calcd for [M+H] + [C 50 H 53 N6O4] + :801.41, found:801.79.HR-MS(ESI + , MeOH):Calcd for [M+MeOH+H] + [C 51 H 57 N6O5] + :833.4385, found:833.4377.

[0056] The main particles of P2TA in methanol solution [P2TA+H + ] + , m / z=801.18(100) and [P2TA+Na + ] +, m / z=823.73(173), the UV-visible absorption spectrum of P2TA shows that it has maximum absorption around 250-300nm, an absorption peak of the S band around 400nm, and four absorption peaks in the Q band of 500-680nm. When excited at 407nm, P2TA has strong fluorescence emission at 634nm and a broad emission peak at 702nm ( Figure 4 The curve a and Figure 5 ).

[0057] Example 6 (Synthesis of P2TA)

[0058] PPIX (34 mg, 0.06 mmol) was ultrasonically dissolved in 2.1 mL of pyridine; 32 mg of HOBt (0.24 mmol), 46 mg of EDCI (0.24 mmol), and 0.16 g of DIPEA (0.24 mmol) were added respectively, and the mixture was stirred at room temperature for 3 h in the dark, and then 69 mg of tyramine (0.36 mmol) was added. After stirring for 3 h, 121 mL of petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain a precipitate, which was then extracted with 50 mL of DCM and 50 mL of water, and then 50 mL of deionized water was added to wash the precipitate three times; after drying with anhydrous sodium sulfate, the precipitate was separated by silica gel column chromatography, and the product was eluted with dichloromethane: ethyl acetate = 4:1 (v:v), and 15.8 mg of purple-red solid was obtained, with a yield of 38%.

[0059] Example 7 (Synthesis of P2TA)

[0060] PPIX (34 mg, 0.06 mmol) was ultrasonically dissolved in 0.34 mL pyridine; 8 mg HOBt (0.06 mmol), 11.5 mg EDCI (0.06 mmol), and 0.04 g DIPEA (0.06 mmol) were added respectively, and the mixture was stirred at room temperature for 3 h in the dark, and then 24 mg tyramine (0.12 mmol) was added. After stirring for 8 h, 3.4 mL petroleum ether was added to the system, and after stirring for 5 min, the precipitate was filtered to obtain a precipitate, which was then extracted with 50 mL DCM and 50 mL water, and then 50 mL deionized water was added to wash the precipitate three times; after drying with anhydrous sodium sulfate, the precipitate was separated by silica gel column chromatography, and the product was eluted with dichloromethane: ethyl acetate = 4: 1 (v: v), and 5 mg purple-red solid was obtained, with a yield of 12%.

[0061] Performance study 1: Effect of solvent and TA dosage on P4TA yield

[0062] TCPP and tyramine (TA) were covalently coupled via amide bonds to form compound P4TA. The effects of solvent and TA dosage on the reaction yield were studied (Table 1 and Table 2). First, we investigated the effects of different solvents on the reaction: when CH2Cl2 and CH3CN were selected as solvents, the target product P4TA was generated in extremely low amounts; when DMF and methanol, two polar solvents, were used, the yields of P4TA were 19% and 36.75%, respectively; it is worth noting that when the alkaline solvent pyridine was used, the yield of the target product P4TA was significantly increased to 68.54%. This phenomenon can be attributed to the fact that pyridine enhances the solubility of TCPP. In addition, the stability of the alkaline environment plays a key role in the formation and maintenance of the intermediate, effectively reducing the formation of by-products, thereby significantly increasing the overall yield of the reaction. Therefore, pyridine was selected as the best solvent for this reaction. The relationship between the TA / TCPP ratio and the yield was further studied (Table 2). The results showed that when the TA / TCPP ratio was in the range of 4 to 12, the yield increased with the increase of the ratio, and reached the maximum value when the ratio reached 12.

[0063] Table 1 Effect of different solvents on P4TA yield [a]

[0064] Solvents Yield / % Pyridine 68.54 DMF(N,N-dimethylformamide) 36.75 MeOH(Methanol) 19 <![CDATA[CH3CN (acetonitrile)]]> 8.62 <![CDATA[CH2Cl2 (Dichloromethane)]]> Trace

[0065] Note: [a] Reaction conditions: 0.06 mmol of TCPP, 0.54 mmol of HOBt, 0.54 mmol of EDCI, 0.54 mmol of DIPEA, 1.2 mmol of TA, N2 and solvent (4 mL) at room temperature.

[0066] Table 2 Effect of TA dosage on P4TA yield

[0067] Ratio (TA / TCPP) Yield / % 4 39.23 8 53.36 12 71.26

[0068] Note: [a] Reaction conditions: 0.06 mmol of TCPP, 0.54 mmol of HOBt, 0.54 mmol of EDCI, 0.54 mmol of DIPEA, 1.2 mmol of TA, N2, and pyridine (4 mL) at room temperature.

[0069] Performance Study 2: Cu 2+ Fluorescence titration experiment of P2TA and P4TA

[0070] Prepare a 1 mM aqueous copper sulfate (CuSO4) solution; under constant stirring at 30°C, add different concentrations (0 μM, 2.5 μM, 5 μM, 7.5 μM, 10 μM) of CuSO4 solution into P2TA or P4TA (7.5 μM, DMSO) solution every 17 min, and use a fluorescence spectrophotometer to test the fluorescence intensity of the solution (the excitation wavelength of P2TA is 406 nm, and the emission wavelength is 633 nm; the excitation wavelength of P4TA is 419 nm, and the emission wavelength is 587 nm).

[0071] The results of the interaction between P2TA and copper ions are shown in Figure 4 , indicating that Cu 2+ The fluorescence emission of P2TA is significantly quenched; the binding effect of P4TA with copper ions is shown in Figure 2 , indicating that P4TA and P2TA have probes that sense copper ion binding.

[0072] Performance study 3: Evaluation of the binding effect of P2TA and P4TA with tyrosinase

[0073] 86.7U / mL tyrosinase (TYR) solution (PBS, pH=6.8) was prepared, and DMSO solutions of P2TA and P4TA of different concentrations (0μM, 3.33μM, 6.66μM, 9.99μM, 13.32μM, 16.65μM, 19.98μM, 23.31μM, 26.64μM, 29.97μM, 33.3μM, 36.63μM, 39.96μM, 43.29μM, 46.62μM) were added dropwise at room temperature, and the effects of P2TA and P4TA on tryptophan and tyrosine in TYR were investigated by synchronous fluorescence method. The binding constant (Ka) and binding ratio (n) of biomolecules and compounds were calculated by fluorescence titration curve, and the equation was the improved Stern-Volmer equation:

[0074]

[0075] Where F0 is the initial fluorescence intensity, F is the fluorescence intensity after adding the compound, and Q is the quencher concentration.

[0076] The data are shown in Table 3, and the effect of P4TA on tyrosinase is shown in Figure 6 and Figure 7 The data in Table 3 show that P2TA and P4TA have good binding effects with the tyrosine group (tyr) and tryptophan (try) group in tyrosinase.

[0077] Table 3 Luminescence spectrum fitting parameters of P2TA and P4TA

[0078] Compound Ka(mL / μM) n <![CDATA[R 2 ]]> <![CDATA[P4TA-Tyr]]> 1127 1.8743 0.98 <![CDATA[P2TA-Tyr]]> 30.9 0.9481 0.99 <![CDATA[P4TA-Try]]> 51.02 0.96 0.98 <![CDATA[P2TA-Try]]> 14.6 2.2723 0.99

[0079] Note: Tyr represents the tyrosine group in tyrosinase; Try represents the tryptophan group in tyrosinase; P4TA-Tyr and P2TA-Try represent the binding of the compound to the tyrosine group in the enzyme; P4TA-Try and P2TA-Try represent the binding of the compound to the tryptophan group in the enzyme.

[0080] Performance study 4: Effects of different concentrations of P2TA and P4TA on tyrosinase activity

[0081] Different concentrations of inhibitors P2TA or P4TA (0μM, 3μM, 6μM, 9μM, 13μM, 16μM, 31μM, 47μM, 63μM, 78μM, 94μM) were dissolved in DMSO-PBS (volume ratio 1:4) aqueous solution. Tyrosinase (800μL, 260U / mL) was then added to each sample to form a compound-enzyme complex system. After the complex system was incubated in a 37°C water bath for 10 minutes, 2.4mL of L-tyrosine (L-Tyr) (enzyme substrate) was added to the system. After stirring for 17 minutes, the changes in the ultraviolet absorption spectrum of the system at 475nm were measured to evaluate the effects of P2TA and P4TA on the activity of tyrosinase. The measurement was performed once every minute, and the inhibition rate I of the compound on the enzyme was calculated according to the following two formulas. The data of P2TA are shown in Table 4, and the data results of P4TA are shown in Table 4. Figure 8 and Table 5.

[0082] Enzyme inhibition rate I = (A3-A4) / (A1-A2)

[0083] A1 is the absorbance with substrate but no inhibitor; A2 is the absorbance with substrate but no inhibitor; A3 is the absorbance with inhibitor and substrate; A4 is the absorbance with inhibitor but no substrate.

[0084] Table 4 shows that the data show that the inhibition rate of 13 μM P2TA on tyrosinase is 49.43; Table 5 shows that the inhibition rate of 9 μM P4TA on tyrosinase is 50.61, and the inhibition rate of 27 μM P4TA on tyrosinase reaches 88.63, which indicates that P4TA is a better tyrosinase inhibitor.

[0085] Table 4 UV-Vis spectra values ​​and enzyme inhibition rate I of A1 to A4 of P2TA-enzyme-substrate system

[0086]

[0087] Table 5 UV-Vis spectra values ​​and enzyme inhibition rate I of A1 to A4 of P4TA-enzyme-substrate system

[0088]

[0089]

Claims

1. An amphiphilic tyrosinase copper competitive binder, characterized in that The structural formula is as follows:

2. The method for preparing the amphiphilic tyrosinase copper competitive binder according to claim 1, characterized in that: The steps include: 4,4',4",4"'-(porphyrin-5,10,15,20-tetrayl)tetrabenzoic acid TCPP or 3,7,12,17-tetramethyl-8,13-diethyl-2,18-porphyrin dipropionic acid PPIX is mixed with pyridine in proportion, and then 1-hydroxybenzotriazole HOBt, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDCI and N,N-diisopropylethylamine DIPEA are added dropwise; then the mixed solution is stirred at room temperature in the dark, and then tyramine TA is added, and the stirring is continued; petroleum ether is added to the above system, and a precipitate is obtained by filtering, and then extracted with DCM and water, dried with anhydrous sodium sulfate, and subjected to rotary distillation or silica gel column chromatography to obtain a purple-red solid P4TA or a purple-red solid P2TA.

3. The preparation method according to claim 2, characterized in that: When the raw material is TCPP, The mass ratio of TCPP to pyridine is 1:10 to 1:60; The molar ratio of TCPP:HOBt:EDCI:DIPEA is 1:1:1:1 to 1:8:8:8; The molar ratio of TCPP:tyramine TA is 1:2 to 1:

16.

4. The preparation method according to claim 3, characterized in that: When the raw material is TCPP, The mass ratio of TCPP to pyridine is 1:40; The molar ratio of TCPP:HOBt:EDCI:DIPEA is 1:3:3:3; The molar ratio of TCPP:tyramine TA is 1:

12.

5. The preparation method according to claim 2, characterized in that: When the raw material is PPIX, The mass ratio of PPIX to pyridine is 1:10 to 1:60; The molar ratio of PPIX:HOBt:EDCI:DIPEA is 1:1:1:1 to 1:4:4:4; The molar ratio of PPIX:tyramine TA is 1:2 to 1:

8.

6. The preparation method according to claim 5, characterized in that: When the raw material is PPIX, The mass ratio of PPIX to pyridine was 1:40; The molar ratio of PPIX:HOBt:EDCI:DIPEA is 1:2:2:2; The molar ratio of PPIX:tyramine TA is 1:

6.

7. The preparation method according to claim 2, characterized in that: The mixed solution is stirred at room temperature in the dark for 1 to 3 hours; after adding tyramine, the stirring time is 3 to 12 hours; The volume ratio of petroleum ether to pyridine is 10:1 to 60:1; during extraction, the volume ratio of DCM to water is 1:

1.

8. The preparation method according to claim 7, characterized in that: The mixed solution was stirred at room temperature in the dark for 1 h; After adding tyramine, the stirring time was 8 h; The volume ratio of petroleum ether to pyridine is 25:

1.

9. Use of the amphiphilic tyrosinase copper competitive binder according to claim 1 for tyrosinase recognition or tyrosinase activity inhibition.

10. Use of the amphiphilic tyrosinase copper competitive binding agent according to claim 9 as a copper competitive binding agent in tyrosinase.

Citation Information

Patent Citations

  • Tyrosinase activity inhibitor

    JP2001240528A

  • New tyrosinase inhibitor extract

    US20050255181A1